公开(公告)号：US20250002922A1

公开(公告)日：2025-01-02

申请号：US18885005

申请日：2024-09-13

Applicant: Six Therapeutics Inc.

Inventor： Howard LEVINE ,  Nyron KHAN ,  Prashant GIRINATH ,  Simon TALBOT

IPC: C12N15/117 ,  A61K9/00 ,  A61P17/02

Abstract: Compositions and pharmaceutical compositions are provided herein which can comprise oligonucleotides, such as synthetic CpG oligonucleotides, related to immune responses, and/or other ingredient(s). Compositions and pharmaceutical compositions described herein include those that result in a TLR9 activation. Also described are methods, among other things, for accelerating wound healing, for cell expansion, and improved methods of activated cell expansion by compositions and pharmaceutical compositions herein.

公开(公告)号：US12098371B2

公开(公告)日：2024-09-24

申请号：US18451013

申请日：2023-08-16

Applicant: Hongene Biotech Corporation

Inventor： Mufa Zou ,  David Yu ,  Aldrich N. K. Lau ,  Ruiming Zou ,  Wing C. Poon ,  Gang Zhao ,  Gengyu Du ,  Yun-Chiao Yao ,  Allen Wong ,  Xiaojun Li

IPC: C12N15/117 ,  B01J19/00

CPC classification number: C12N15/117 ,  B01J19/0046 ,  C12N2310/14 ,  C12N2310/17 ,  C12N2310/3515

Abstract: Embodiments of the present disclosure relate to lipid-PEGylated solid support and phosphoramidites derivatives, methods for preparing the same, and their uses in the delivery of oligonucleotide drugs to the cellular targets.

公开(公告)号：US12098369B2

公开(公告)日：2024-09-24

申请号：US18075085

申请日：2022-12-05

Applicant: Helix Nanotechnologies, Inc.

Inventor： Nikhil Dhar ,  Marianna Keaveney ,  Kyle Backman ,  Everett Webster ,  Nikolai Eroshenko ,  Justin Quinn

IPC: C07H21/04 ,  C12N15/113 ,  C12N15/117

CPC classification number: C12N15/113 ,  C12N15/117 ,  C12N2310/141 ,  C12N2310/334 ,  C12N2310/335

Abstract: Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising N4-acetylcytidine and/or 5-hydroxymethyluridine, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present disclosure and methods of making and using the same.

公开(公告)号：US12029760B2

公开(公告)日：2024-07-09

申请号：US16609628

申请日：2018-05-02

Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Inventor： Yangbing Zhao ,  Jiangtao Ren

IPC: A61K35/17 ,  C12N9/22 ,  C12N15/10 ,  C12N15/117 ,  C12N15/90 ,  A61K39/00 ,  A61P35/00 ,  A61P37/02

CPC classification number: A61K35/17 ,  C12N9/22 ,  C12N15/102 ,  C12N15/117 ,  C12N15/90 ,  A61K2039/5158 ,  A61P35/00 ,  A61P37/02 ,  C12N2310/122 ,  C12N2310/20 ,  C12N2310/315

Abstract: The present invention includes compositions and methods for modifying primary T cells. In one aspect, the invention comprises administering to a cell a stem-loop Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) RNA (st-crRNA) and a Cpf1 enzyme.

公开(公告)号：US20240158802A1

公开(公告)日：2024-05-16

申请号：US18520449

申请日：2023-11-27

Applicant: Nutcracker Therapeutics, Inc.

Inventor： Samuel DEUTSCH ,  Daniel FRIMANNSSON ,  Nicole FAY ,  Colin McKINLAY ,  Ole HAABETH

IPC: C12N15/117 ,  A61K9/14 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28

CPC classification number: C12N15/117 ,  A61K9/145 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2818

Abstract: Provided herein are examples of mRNA treatment nanoparticles and methods of using them to treat a patient. An mRNA treatment nanoparticle may include one or more mRNAs encoding a tumor-specific antigen and an immunomodulatory agent; and a delivery vehicle molecule encapsulating the one or more mRNAs.

公开(公告)号：US20240158801A1

公开(公告)日：2024-05-16

申请号：US18393461

申请日：2023-12-21

Applicant: UNIVERSITY OF MIAMI

Inventor： Glen N Barber

IPC: C12N15/117 ,  A61K9/127 ,  A61K31/713 ,  A61K39/00 ,  A61K39/39 ,  A61P35/00 ,  B82Y5/00 ,  C12N5/0784 ,  C12N15/88

CPC classification number: C12N15/117 ,  A61K9/127 ,  A61K31/713 ,  A61K39/0011 ,  A61K39/39 ,  A61K39/4615 ,  A61K39/4622 ,  A61K39/464499 ,  A61P35/00 ,  B82Y5/00 ,  C12N5/0639 ,  C12N15/88 ,  A61K2039/5152 ,  A61K2039/55561 ,  A61K2039/585 ,  C12N2501/2301 ,  C12N2501/25 ,  C12N2502/30 ,  C12N2502/99

Abstract: Activation of STimulator of INterferon Genes (STING) triggers cytokine production and facilitates tumor antigen cross-presentation. In an embodiment of the present invention, STING-dependent innate immune signaling pathway activators (STAVs) can be delivered to antigen presenting cells. In various embodiments of the present invention, the STAVs can be delivered in lipid nanoparticle formulations. In various embodiments of the present invention, the range of cancers amenable to STAV therapy can be extended using a non-cell-based nanoparticle strategy that effectively delivers Nano-STAVs into the Tumor Micro Environment (TME) to potently generate anti-tumor cytotoxic T cell activity. The STAV formulations can be introduced into solid tumors present in the mammal. Alternatively, the Nano-STAVs can be introduced through direct inoculation. The lipid nanoparticles stick to the tumor cells and are co-phagocytosed to activate STING in APC's.

公开(公告)号：US20240131194A1

公开(公告)日：2024-04-25

申请号：US18471738

申请日：2023-09-20

Applicant: The Trustees of the University of Pennsylvania

Inventor： Katalin Kariko ,  Drew Weissman

IPC: A61K48/00 ,  A61K38/17 ,  A61K38/18 ,  A61K38/50 ,  C07H21/02 ,  C07K14/47 ,  C07K14/505 ,  C12N5/071 ,  C12N5/074 ,  C12N15/117 ,  C12N15/67 ,  C12N15/85 ,  C12Q1/68

CPC classification number: A61K48/0066 ,  A61K38/177 ,  A61K38/1816 ,  A61K38/50 ,  A61K48/0041 ,  A61K48/005 ,  A61K48/0075 ,  C07H21/02 ,  C07K14/47 ,  C07K14/4712 ,  C07K14/505 ,  C12N5/0602 ,  C12N5/0696 ,  C12N15/117 ,  C12N15/67 ,  C12N15/85 ,  C12Q1/68 ,  C12Y305/04004 ,  A61K48/00 ,  C12N2310/17 ,  C12N2310/33 ,  C12N2310/3341 ,  C12N2501/40 ,  C12N2800/95

Abstract: This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of RNA, oligoribonucleotide, and polyribonucleotide molecules.

公开(公告)号：US11905514B2

公开(公告)日：2024-02-20

申请号：US18080164

申请日：2022-12-13

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Andrew Geall

IPC: C12N15/117 ,  C12N15/86 ,  A61K39/155 ,  A61K39/39 ,  A61K39/12 ,  A61P31/12 ,  A61P37/04 ,  A61K48/00 ,  A61K39/00

CPC classification number: C12N15/117 ,  A61K39/12 ,  A61K39/155 ,  A61K39/39 ,  A61K48/0041 ,  A61K48/0083 ,  A61P31/12 ,  A61P37/04 ,  C12N15/86 ,  A61K2039/53 ,  A61K2039/552 ,  A61K2039/55555 ,  A61K2039/55566 ,  C12N2760/18534 ,  C12N2770/36143 ,  C12N2820/60

Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 μg and 100 μg. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 μg and 100 μg of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.

公开(公告)号：US11898147B2

公开(公告)日：2024-02-13

申请号：US17467390

申请日：2021-09-06

Applicant: National Health Research Institutes

Inventor： Tsung-Hsien Chuang ,  Jen-Chih Tseng ,  Jing-Xing Yang ,  Yi-Ling Liu

IPC: C07H21/02 ,  C12N15/117 ,  C07K16/28 ,  A61P35/00 ,  A61K31/711

CPC classification number: C12N15/117 ,  A61K31/711 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827

Abstract: The present invention discloses a combinational therapy for enhancing efficacy of immune checkpoint blockade for tumors with immune suppressive microenvironment. More specifically, this combination therapy involves the treatment of cancer through immune checkpoint inhibitors and CpG-oligodeoxynucleotides.

公开(公告)号：US11891608B2

公开(公告)日：2024-02-06

申请号：US18080150

申请日：2022-12-13

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Andrew Geall

IPC: C12N15/117 ,  C12N15/86 ,  A61K39/155 ,  A61K39/39 ,  A61K39/12 ,  A61P31/12 ,  A61P37/04 ,  A61K48/00 ,  A61K39/00

CPC classification number: C12N15/117 ,  A61K39/12 ,  A61K39/155 ,  A61K39/39 ,  A61K48/0041 ,  A61K48/0083 ,  A61P31/12 ,  A61P37/04 ,  C12N15/86 ,  A61K2039/53 ,  A61K2039/552 ,  A61K2039/55555 ,  A61K2039/55566 ,  C12N2760/18534 ,  C12N2770/36143 ,  C12N2820/60

Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 μg and 100 μg. Thus, the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 μg and 100 μg of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.